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SUMMARY 
Background 
Antipsychotic drugs might cause acutely-occurring serious side effects and thus contribute to 
the increased physical morbidity and mortality observed in patients with severe mental 
disorders. We examined this hypothesis by conducting a meta-analysis of ICH-GCP-defined 
serious adverse events (SAEs) occurring in placebo-controlled trials of antipsychotics. 
Methods 
For this systematic review and meta-analysis (PROSPERO #CRD42016033930), we included 
randomised controlled trials (RCTs) comparing second-generation antipsychotics with placebo 
across diagnostic categories. We searched MEDLINE, EMBASE, Cochrane CENTRAL, 
BIOSIS, PsycINFO, Pubmed, Clinicaltrials.gov and WHO ICTRP (last search 01/27/2017) for 
eligible trials. We contacted pharmaceutical companies, drug regulatory authorities and study 
investigators for additional data. The primary outcome was the number of patients with at least 
one somatic SAE. We estimated minimum and maximum numbers of patients with the outcome 
in each study arm and synthesized the results with Odds Ratios in a common-effects meta-
analysis.  
Findings 
We identified 597 RCTs comprising 108664 participants. 314 trials (67642 participants) with 
details on individual SAEs available constituted the main dataset for meta-analysis. 88% of 
these were 13 weeks (3 month) or shorter in duration (median 6, IQR 4-9 weeks). At least one 
somatic SAE occurred in minimally 698 to maximally 862 of 42600 patients (1.63-2.02%) on 
antipsychotics and in minimally 343 to maximally 419 of 25042 (1.37%-1.67%) patients on 
placebo. The odds ratios were 1.24 (95%CI 1.08, 1.42) and 1.24 (95%CI 1.10, 1.41) based on 
the minimum and maximum estimate respectively. In predefined subgroup-analyses we found 
evidence suggesting a larger effect in elderly patients (OR 1.56; 95%CI 1.22, 1.98)/OR 1.58; 
95%CI 1.25, 1.99) as compared to adults (OR 1.09; 95%CI 0.91, 1.29)/OR 1.10; 95%CI 0.95, 
1.28); likewise in children/adolescents although the evidence was weaker (OR 1.49; 95%CI 
0.81, 2.75/OR 1.54; 95%CI 0.85, 2.77).  
Interpretation 
We found evidence that antipsychotics cause short-term somatic SAEs on top of somatic SAEs 
occurring independent of treatment. This effect appears to be mainly driven by results in elderly 
patients. Hence, clinicians should be aware that antipsychotics are potentially toxic, particularly 
when treating patients sharing risk factors with the elderly population. 
Funding 
German Ministry of Education and Research (FKZ01KG1505) 
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INTRODUCTION 
Patients with schizophrenia and other severe mental disorders have higher rates of physical 
disorders1,2 and live on average 14.5 years less compared to the general population.3 Treatment 
with antipsychotic drugs is suspected to contribute to the increased morbidity and mortality by 
causing acutely-occurring serious side effects and through the consequences of chronically-
persisting side effects such as weight gain. Indeed, in observational data use of antipsychotics 
has been associated with higher incidences of several serious physical disorders that may arise 
from acutely-occurring side effects, such as thromboembolisms, diabetic ketoacidosis, cardiac 
arrhythmias, pneumonia, hepatic injuries, seizures, malignant neuroleptic syndrome, or 
leukocytopenia and agranulocytosis.4 However, association is not always due to causality. 
Associations found in observational data may be confounded by factors such as differences in 
severity of illness, comorbidities, health-relevant life style, or utilization and access to health 
care between treated patients and controls.4   
Randomised controlled trials (RCTs) are considered the best study design to examine causality 
and in modern RCTs it is mandatory to record serious adverse events (SAE)5,6 as part of 
International-Council-for-Harmonization-Good-Clinical-Practice (ICH-GCP) guidelines.7 A 
SAE is defined as any untoward medical occurrence at any dose that results in death, is life-
threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results 
in persistent or significant disability or is a congenital anomaly or birth defect. By meta-
analyzing SAEs that occurred in RCTs comparing antipsychotic drugs to placebo, we aimed to 
examine whether antipsychotics cause (directly or indirectly) acutely-occurring serious side 
effects (of any kind) and thus contribute to the observed increased morbidity and mortality in 
patients with severe mental disorders. Hereby, we complement our previously published meta-
analysis on short-term mortality in placebo-controlled RCTs of antipsychotics.8 To our 
knowledge, this is the first analysis of this kind (see research in context).  
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METHODS 
This systematic review and meta-analysis was conducted in the context of a broader project 
sponsored by the German Ministry of Education and Research which also comprises an 
assessment of mortality reported previously.8 The analysis of mortality used the same literature 
search and methods (inclusion criteria, statistical methods, sensitivity and subgroup/meta-
regression analyses), but analyzed as outcome mortality (irrespective whether fatal events were 
reported as SAE or not). The protocol for both analyses (mortality, SAEs) was published in 
PROSPERO (#CRD42016033930, appendix). In reporting the meta-analysis, we followed the 
PRISMA statement9 (checklist in appendix). 
 
Search strategy and selection criteria 
We included randomised controlled trials (RCTs) comparing second-generation antipsychotic 
drugs (SGAs) to placebo across any indications. Thus patients in a wide range of diagnostic 
categories (e.g., schizophrenia, bipolar disorder, major depression, dementia, autism) were 
eligible, because we assumed that side effects occur largely independent of the treated mental 
disease. There were no limitations in age, sex or ethnicity of the study populations. 
 
We included studies that compared placebo to any SGA currently available in the US or Europe, 
i.e., amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, 
lurasidone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, ziprasidone and 
zotepine.  We also included first-generation antipsychotics (FGAs) that were used as additional 
active comparators in placebo-controlled trials of SGAs. There were no restrictions in mode of 
application (oral, intravenous, inhalers, short- and long-acting (depot) intramuscular 
applications), doses (any dose, in flexible and fixed dosing regimens), or additional treatments 
(monotherapy or add-on treatment). 
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We included double-blind, single-blind, and open-label RCTs. However, we excluded a priori 
studies with a high risk of bias in sequence generation for randomisation or allocation 
concealment.10 There was no restriction in terms of study duration. Only very short studies (≤24 
hours) measuring psychological reactions to drugs (e.g. fMRI studies) were excluded. In 
general, we included studies irrespective of publication year and language. However, we 
excluded studies conducted in mainland China because of major concerns about study 
quality.11–14 
 
To identify eligible studies, we searched the electronic databases MEDLINE, EMBASE, 
Cochrane CENTRAL, BIOSIS, PsycINFO, Pubmed, Clinicaltrials.gov and WHO ICTRP (all 
from inception, last search 01/27/2017). The search strategy used terms for randomisation, the 
generic names of the included second-generation antipsychotics and terms for placebo (see 
appendix for details). Additionally, we manually searched the European Union Clinical Trials 
Register (EUCTR). We also contacted the manufacturers of the antipsychotics, the Food and 
Drug Administration (FDA), the European Medicines Agency (EMA), and the German 
“Bundesinstitut für Arzneimittel und Medizinprodukte” (BfArM), and searched their clinical 
trial websites. Moreover, we contacted all corresponding authors of the included trials for 
missing information. 
 
JS-T, HR and LR, in duplicate, screened the identified references and selected the finally 
included studies. Also in duplicate, JS-T, CD, IB, HR, LR, MH and MK extracted data using 
an electronic database (this system checked automatically whether independent extractions 
agreed) and assessed the risk of bias of the included studies using the Cochrane-risk-of-bias-
tool-I10 (overall risk of bias evaluation performed according to Cipriani et al. 201815). 
Disagreement was resolved by discussion among reviewers or with a third reviewer (JS-T or 
SL). JS-T and SL contacted drug regulatory authorities and pharmaceutical companies and sent 
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personalized emails to all corresponding authors (including authors of protocols without usable 
data, see figure 1) with requests for missing data. 
 
Data analysis 
The primary outcome was the number of patients with at least one somatic serious adverse event 
(SAE) per study arm. As secondary outcomes we examined the number of patients with at least 
one psychiatric SAE and the number of patients with at least one SAE (any SAE, somatic or 
psychiatric). We separated somatic from psychiatric SAEs because according to the broad 
definition of SAEs (see introduction) exacerbations of the treated psychiatric disorders 
(typically leading to hospitalization) are also reported as SAEs. However, such psychiatric 
SAEs rather reflect treatment-inefficacy, and not serious side effects which are the focus of our 
analysis.  We used all reported SAEs and not only SAEs that were attributed to the drug by the 
original study investigators (ICH-GCP-defined serious adverse reactions (SAR)16). The reasons 
were that information on SARs was only rarely reported and that we did not want to base our 
analysis on subjective judgement of original trial investigators (SARs were analyzed in a 
sensitivity analysis).  
As the number of patients with at least one somatic or psychiatric SAE was typically not 
provided in reports of clinical trials, we estimated it from listings of individual SAEs. Therefore, 
we classified individual SAEs according to the Medical-Dictionary-for-Regulatory-Activities 
(MedDRA)17 and considered events categorized in the system-organ-class (SOC) “Psychiatric 
disorder” as psychiatric SAEs. All others we considered somatic SAEs. Because individual 
patients could have had more than one SAE, we estimated the minimum and maximum number 
of patients with at least one somatic (psychiatric) SAE. See appendix for a detailed explanation 
of how the estimates were calculated. 
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We analyzed the data using the common-effect (“fixed-effect”) Mantel-Haenszel meta-analysis 
model with odds ratios (OR) because estimation of heterogeneity is difficult for rare events. 
With this decision we followed the Cochrane Handbook which suggests “incorporation of 
heterogeneity into an estimate of a treatment effect should be a secondary consideration when 
attempting to produce estimates of effects from sparse data – the primary concern is to discern 
whether there is any signal of an effect in the data”.10,18 We synthesized OR and not hazard 
ratios because time-to-event data were usually not reported. The Mantel-Haenszel-method uses 
only studies with at least one event (number of used studies and included patients provided in 
tables of results). In sensitivity analyses we examined models including studies with zero 
events18,19 or models assuming random effects. We included SAEs that occurred in the 
randomised phase or within the studies’ predefined safety follow-up phases after study 
discontinuation or completion (usually lasting 30 days). From cross-over studies we used only 
the first phases to avoid carry-over effects.20 We assessed heterogeneity statistically by 
estimating  τ2, I2 and by performing a Q-test.10 We examined the presence of small study effects 
(linked with the possibility of publication bias) by visually inspecting funnel plots and 
performing Harbord-tests.21 
 
We performed several pre-planned sensitivity analyses to examine the robustness of our results 
for the primary outcome: 
  
1) We only included SAEs that occurred during the randomised phase or within 24 hours 
after the last drug administration, i.e., we excluded SAEs that occurred in the safety-
follow up. The reason was that effects of the randomised drug may be diluted in the 
safety follow-up because patients do not follow strict study conditions anymore, e.g., 
they may not take the study drug but may take others, or no drugs. 
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2) We analyzed incidence rates, i.e., we used the number of patients with at least one 
somatic SAE and the total patient-years per study arm. The reason was that there may 
be differences in premature study discontinuation between drug- and placebo-arms that 
could affect the primary effect size measure (odds ratio). If information about the total 
patient-years spent in the study was not available, it was estimated from study duration 
and number of dropouts, after assuming a linear rate of discontinuation over time. 
3) We analyzed the data using different models for meta-analysis, i.e. Peto’s odds ratios, a 
correlated beta-binomial (Sarmanov) model, Bayesian common-effects and random-
effects models. For the latter we used an informative prior distribution for 
heterogeneity.22 Of note, the beta-binomial model and the Bayesian models use 
information from studies without SAE.  
4) We analyzed SAEs judged as at least possibly treatment-related by original study 
investigators separately (SARs, including suspected unexpected SARs (SUSARs)). 
5) We only included double-blind studies. 
 
We performed several pre-planned subgroup and meta-regression analyses of the primary 
outcome to examine potential treatment effect modifiers. 
 
Separate (univariate) subgroup analyses addressed: 
1) Study duration (<6 days; 6 days to 13 weeks; >13 weeks). 
2) Age groups (children and adolescents; adults; elderly). 
3) Diagnostic category. 
4) Specific antipsychotic used. 
5) Monotherapy versus combinations of antipsychotics (any systematic combination; add-
on to antidepressants, mood stabilizers or antipsychotics). 
6) First-generation versus second-generation antipsychotics. 
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7) Sponsorship by pharmaceutical companies. 
 
Separate (univariate) meta-regression analyses addressed:  
1) The proportion of women enrolled. 
2) Antipsychotic dose in olanzapine equivalents, calculated based on the International 
Consensus Study of Antipsychotic Dosing.23 Here, only studies of oral drugs in adult 
patients were included because dose equivalencies are not well specified for other age 
groups and applications. 
 
For our main findings, we additionally estimated risk differences (RDs) based on summary ORs 
and incidences on placebo as baseline risk. Risk differences are often preferred for reasons of 
interpretability.10 However, readers must be aware that RDs are conditional on baseline risk, 
which may be different in other settings. 
 
Post-hoc, we analyzed somatic SAEs grouped by individual MedDRA-SOCs17 (overall, by age 
group and for the diagnostic categories schizophrenia and dementia).  
 
We performed meta-analysis using the Mantel-Haenszel and Peto methods in R24 using the 
package meta.25 We fitted the correlated beta-binomial model in R using the code provided by 
Chen et al.26 We synthesized incidence rates in R using the metafor package,27 fitting a 
random-effects generalized linear model with a Poisson likelihood. We performed all Bayesian 
analysis in OpenBUGS.28,29 See appendix for details of the statistical models.  
The strength of the evidence was assessed with the GRADE framework30 using the online tool 
GRADE PRO (https://gradepro.org/). 
 
Role of the funding source 
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The funder of the study had no role in study design, data collection, data analysis, data 
interpretation or writing of the report. The corresponding author had full access to all the data 
in the study and had final responsibility for the decision to submit for publication. 
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RESULTS 
We present the PRISMA9 flow diagram in figure 1 and the characteristics of included studies 
in the appendix. We identified 597 RCTs (dating from 1978 to 2017) with a total of 108664 
participants.  
368 trials (89731 patients) reported whether any SAE occurred in the included patients. Out of 
these, 314 trials (67642 patients) reported details about individual SAEs, which allowed us to 
estimate the minimum and maximum number of patients with at least one somatic SAE. These 
314 studies constitute our main dataset. In the main dataset, most patients’ illnesses were in the 
diagnostic categories of schizophrenia (42% of all patients), bipolar disorder (30%), major 
depressive disorder (11%) and dementia (6%). The remaining patients (11%) were in an 
additional 17 officially-approved or off-label indications for antipsychotics. Most patients 
(83%) were adults (in trials typically defined as 18-65 years), 8% elderly (typically >65 years) 
and 9% children and adolescents (typically <18y). 46% of patients were women. The most 
frequently used drugs were olanzapine (17% of 42600 patients treated with active drug), 
aripiprazole (16%), quetiapine (11%), paliperidone (11%), risperidone (11%), asenapine (7%), 
lurasidone (7%) and brexpiprazole (6%); the remaining 14% of patients were treated with 7 
additional antipsychotics (including the first-generation antipsychotics (FGAs) haloperidol 
(5%) and chlorpromazine (0.2%) used as active comparators in placebo-controlled studies of 
SGAs). 306 (97%) trials were double blind. 263 (84%) were sponsored by pharmaceutical 
companies. The median duration of trials was 6 weeks (IQR 4-9 weeks). 276 (87.9%) trials 
were 13 weeks (3 months) or less in duration. None of the included studies was set out to 
specifically examine serious adverse events as the main outcome. 
We present the risk of bias assessment in the appendix. We conservatively judged all studies 
for which we could not acquire information about individual SAEs at risk of selective reporting. 
Therefore, 254 of 597 trials (43%) were rated at high risk of bias in this category. Ratings of 
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high risk of bias were rare in other categories: none of 597 for randomisation, none for 
allocation concealment, 19 (3%) for blinding of participants and personal, 14 (2%) for blinding 
of outcome assessment, 11 (2%) for incomplete outcome data, and 15 (3%) for other sources 
bias. In the overall risk of bias evaluation 30 trials (5%) were rated at high, 358 (60%) at 
moderate and 209 (35%) at low risk of bias. 
 
In all the following results, an odds ratio >1 corresponds to higher odds of SAEs with 
antipsychotics (favors placebo). Note that for rare events, odds and risks become very similar; 
hence, we also use the word “risk” instead of “odds” for reasons of readability. 
 
Somatic SAEs (the primary outcome) were reported for minimally 698 to maximally 862 of 
42600 patients (1.63-2.02%) randomised to antipsychotics and for 343 to 419 of 25042 (1.37%-
1.67%) patients randomised to placebo (table 1). The summary OR was 1.24 for both analyses, 
i.e., using either the minimum or the maximum number of patients with at least one event. The 
95% CIs ranged from 1.10 to 1.41 and from 1.08 to 1.42, respectively (k=196 studies, n=57850 
patients). These results indicate an increased risk of somatic SAEs for patients exposed to 
antipsychotic drugs. 
Psychiatric SAEs (secondary outcome) were reported for 1038 to 1161 of 67598 patients 
randomised to antipsychotics (2.4%-2.7%) and 846 to 921 of 24992 patients randomised to 
placebo (3.4%-3.7%). The summary OR were 0.64 (95%CI 0.58, 0.71) and 0.67 (95%CI 0.61, 
0.73) based on the minimum and maximum number of patients respectively (k=186, n=56381). 
These results indicate an increased risk of psychiatric SAEs for patients exposed to placebo. 
Any SAEs (secondary outcome), without distinguishing between somatic and psychiatric 
SAEs, were reported for 2445 of 56870 patients randomised to antipsychotics (4.3%) and 1639 
of 32861 patients randomised to placebo (5%). The summary OR was 0.83 (95% CI 0.77, 0.89, 
k=276, n=84999) indicating an increased risk of any SAE for patients exposed to placebo. 
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Sensitivity analyses yielded results similar to the primary analysis (somatic SAEs) (table 2).  
 
In subgroup analyses (table 3) we only found some evidence of effect modification according 
to age. More specifically,  studies in elderly patients (OR 1.56; 95%CI 1.22, 1.98)/OR 1.58; 
95%CI 1.25, 1.99)  as well as in children/adolescent patients (OR 1.49; 95%CI 0.81, 2.75/OR 
1.54; 95%CI 0.85, 2.77) showed a higher risk of somatic SAEs as compared to studies in adults 
(OR 1.09; 95%CI 0.91, 1.29/OR 1.10; 95%CI 0.95, 1.28). 
 
The meta-regression analysis on proportion of women did not show evidence of a differential 
effect. The meta-regression on dosage provided some evidence that the risk for somatic SAEs 
increases with the mean dose applied in studies (regression coefficient based on minimum 
estimate 0.017 (95%CI -0.003, 0.037); based on maximum estimate 0.023 (95%CI 0.004, 
0.043)), corresponding to ORs rising gradually from 0.96/0.90 for studies with a mean dose of 
5 mg to 1.25/1.27 for studies with a mean dose of 20 mg olanzapine equivalents.  
 
There was no indication of small study effects (Harbord test p=0.12 for minimum, p=0.26 for 
maximum estimate; funnel-plots in appendix).  
 
Overall there was little evidence for heterogeneity in both analyses of the primary outcome 
(minimum and maximum estimate). A visual inspection of the forest-plots (appendix) indicated 
some discrepancy between the studies estimates. The Q test for heterogeneity did not reject the 
null hypothesis of homogeneity, p-value 1.00 (minimum) and 0.97 (maximum estimate). The 
DerSimonian-and-Laird estimator for 𝜏𝜏2was zero in both analyses. 
However, estimation of heterogeneity in an analysis of rare events, such as SAEs, can be 
difficult. Therefore, in order to assess the robustness of our results, we also performed a 
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Bayesian sensitivity analysis including external information in the form of informative prior 
distributions22 for heterogeneity. This analysis did not give markedly different results from the 
primary analysis (table 2).  
 
The strength of the evidence was rated to be moderate for the primary outcome according to 
GRADE (evidence profile in appendix).30 
 
Overall, our results correspond to RDs of 4/4 (minimally/maximally) more patients with 
somatic SAEs among 1000 treated (95%CI ranging from 2/2 more to 6/7 more); in adults 1/2 
more (95%CI 1/1 less, 5/4 more); in children/adolescents 4/5 more (95%CI 2/2 less, 17/19 
more); in elderly 29/32 more (95%CI 12/15 more, 49/54 more). 
 
Post-hoc, to explore which kind of SAEs contributed to the observed increased risk, we 
analyzed somatic SAEs grouped by MedDRA-System-Organ-Classes (SOCs) (table 5). In the 
total sample, we found  indications of differences between drug and placebo for A) “Infections 
and infestations”, B) “Musculoskeletal and connective tissue disorders”, C) “Nervous system 
disorders”, D) “Respiratory, thoracic and mediastinal disorders“ and E) “Surgical and medical 
procedures”. In the elderly subgroup (appendix) we additionally found indications for F) 
“Cardiac disorders”, G) “Injury, poisoning and procedural complications” and H) “Vascular 
disorders”. 
Within these SOCs the following MedDRA-subcategories – selected for specificity of the term 
– showed the highest absolute differences between drug and placebo (appendix: SAEs classified 
by MedDRA-hierarchy): “Lower respiratory tract and lung infections” (within A), 
“Rhabdomyolysis” (B), “Movement disorders” (C), “Central nervous system vascular 
disorders” (C), “Disturbances in consciousness NEC” (C; mainly syncope, somnolence and 
stupor), “Bronchospasm and obstruction” (D), and “Psychosocial support” (E).  Except for 
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“Rhabdomyolysis” “and “Movement disorders”, differences between drug and placebo were 
most prominent in elderly patients. In addition to the MedDRA-subcategories just mentioned 
in elderly also “Pneumonia aspiration” (D), “Surgery” (E), “Cardiac arrhythmias” (F), “Heart 
failures” (F), “Injury NEC” (G), “Hypotension” (H) and “Embolism and thrombosis” (H) were 
numerically increased with antipsychotics. There was no specific type of SAEs that explains 
the trend for an increased risk in children/adolescents. 
Of note, statistical power was low, SOCs are broad categories and there may be chance findings 
due to multiple-testing; moreover, the selected MedDRA-subcategories are descriptive only. 
Consequently, there is limited evidence that the observed overall effect is due to differences in 
the mentioned categories and also other disorders may contribute. We emphasize that our results 
regarding specific disorders should thus be considered exploratory and hypothesis generating 
rather than confirmatory.  
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DISCUSSION 
In this systematic review and meta-analysis of 597 randomised controlled trials (comprising 
108664 participants) we found evidence of an increased risk of somatic serious adverse events 
in patients treated with antipsychotic drugs as compared to patients treated with placebo. This 
result was consistent in several sensitivity analyses. Subgroup analyses suggested age as a 
potential treatment effect modifier with the highest risk found in studies in elderly patients, but 
also in studies with children/adolescents, although the evidence was weaker for the latter 
category. 
 
A conceptual strength of the analysis is that it was based on randomised trials with a large total 
sample size (67642 patients from 314 trials in the meta-analysis of somatic SAEs). Thus it can 
be expected that all potential confounders were equally distributed across drug and placebo 
groups. 
Specific strengths are the extensive search and the use of ICH-GCP-defined7 SAEs as an 
outcome, which are by definition selected for seriousness. We faced the issue that often SAEs 
were not reported or only the total number of patients with any SAE was provided. “Any SAE” 
is however a problematic outcome because it includes inefficacy-related psychiatric SAEs 
which are not relevant for assessing tolerability (and which are more frequent with placebo, see 
table 1). To overcome this problem, we extensively requested additional data (obtained for 244 
trials) and, thus, could specifically estimate the risk of somatic SAEs – an outcome focusing on 
side effects. For future trials, we urge that somatic and psychiatric SAEs should be always 
reported separately.  
 
Our analysis has limitations. First, we could not obtain details about specific SAEs for 54 
studies which reported that at least one SAE occurred; for 229 studies we could not obtain 
information on SAEs at all; and for 72 studies we only found protocols. We deem it unlikely 
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for most studies (see appendix: GRADE), but it cannot be excluded that in some studies 
information on somatic SAEs was suppressed intentionally (selective reporting), or that some 
planned studies were not published because of unfavorable safety data (publication bias). 
Second, although required by regulatory authorities, some SAEs may not have been assessed 
and reported31 (underreporting of adverse events is a general weakness of safety data from 
clinical trials). Third, sponsorship by pharmaceutical companies, as in most included trials, 
needs to be considered. Fourth, non-adherence to study medication may have diluted some of 
the differential effect. And fifth, particularly vulnerable patients with severe somatic 
comorbidities were often excluded from RCTs. These first five limitations potentially led to an 
underestimation of the incidences of somatic SAEs and/or the risk associated with 
antipsychotics relative to placebo. Mainly due to the probable underestimation of the effects as 
compared to routine care resulting from these limitations, we downgraded the strength of the 
evidence to moderate (appendix: GRADE). 
Sixth, the available RCTs were mainly short-term in duration (88%≤3 month). Consequently, 
we could not examine the risk of somatic SAEs related to chronically-persisting side effects of 
antipsychotics (e.g. weight gain). Seventh, event histories and information whether original 
investigators judged individual SAEs treatment-related (SAR) were often not reported. Thus, 
important indications which specific disorders might be increased by antipsychotics were 
missing (nevertheless 110 SARs could be tabulated (appendix)). Eighth, the subgroup analysis 
on specific drugs is limited in statistical power and by potential confounding (e.g. some 
antipsychotics were tested for dementia, others not). Further analyses including head-to-head-
studies are needed to examine differences between antipsychotics. Ninth, we did not examine 
whether the method of dose increase of antipsychotics (rapid or slow) had an effect on 
occurrence of somatic SAEs. Finally, we acknowledge that the last search for eligible studies 
was conducted over 2 years ago (01/27/2017). Thus, some recently-published placebo-
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controlled studies were not included. However, we deem it unlikely that data of these trials 
would change the overall results (based on 597 studies published in 39 years). 
 
Despite these limitations, our analysis provides randomised evidence that antipsychotic 
exposure can induce or aggravate serious somatic disorders – as suggested by associations 
found in observational studies.4 In line with observational studies,4,32,33 elderly patients and 
children/adolescents appeared particularly vulnerable also in our dataset. Concerning specific 
disorders possibly increased by antipsychotics, our exploratory and descriptive post-hoc-
analyses suggested several MedDRA-subcategories. For all of them associations with 
antipsychotics have been observed in real-world-populations.4,34–42 Yet, as we note in the results 
section, our approach for specific disorders is descriptive and other disorders may also be 
relevant – see appendix: tables of  3942 observed SAEs (and 110 SARs) classified by 
MedDRA-hierarchy (overall, by age group, and for the diagnostic categories schizophrenia and 
dementia). Of note, some SAEs may be indirect effects of treatment, e.g. drug-induced sedation 
and subsequent fall may result in the SAEs “fracture” and “pneumonia” (developed during 
hospitalization). More targeted approaches, such as Standardized-MedDRA-Queries (SMQs), 
applied in analyses focusing on specific disorders are required. For this reason and to avoid 
multiple post-hoc-analyses, we refrained from further analyzing specific disorders. 
 
To put the results in relationship to our previous analysis on mortality,8 approximately 20% of 
patients with a somatic SAE died (30% of elderly, 8% of adults, 0% of children). Subgroup 
analyses suggested increased mortality in elderly (mainly demented) patients and possibly 
increased somatic SAEs and reasons of deaths (appendix) overlap. In the total sample, 
pneumonia, overdose, injury, cerebrovascular disorder, and pneumonia aspiration were the 
reasons of deaths with the highest absolute difference between drug and placebo; except 
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overdose they occurred mainly in elderly patients; in elderly also deaths due to cardiac failure 
were numerically increased. But these results are purely descriptive. 
 
For clinical practice, we note that most occurring somatic SAEs were not related to the drug 
(incidence on placebo ca. 80% of incidence on drug). But on top of independently occurring 
events, antipsychotics led to 4 more patients with somatic SAEs per 1000 treated overall (adults 
1-2; children/adolescents 4-5; elderly 29-32). We deem that this risk is not negligible, but that 
it may be acceptable in physically fit adults, despite possible underestimations, because 
substantial benefit can be expected. Individual patients sharing risk factors with the elderly 
population (e.g. somatic comorbidities, polypharmacy, higher age), and possibly 
children/adolescents, can be more vulnerable. 
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RESEARCH IN CONTEXT 
Evidence before this study 
Morbidity and mortality is increased in patients with schizophrenia and other severe mental 
disorders as compared to the general population. The reasons, however, are not completely 
understood. Treatment with antipsychotic drugs might play a role by causing acutely-occurring 
serious side effects and through the consequences of chronically-persisting side effects. In 
observational data use of antipsychotics has been associated with several serious physical 
disorders that may arise from acutely-occurring side effects. However, using observational data 
it is hard to determine whether antipsychotics actually cause these disorders or whether the 
association is only mediated by confounding factors. 
Randomised controlled trials (RCTs) are considered the best study design to examine causality 
and in modern RCTs it is mandatory to record ICH-GCP-defined serious adverse events 
(SAEs). A meta-analysis of SAEs occurring in placebo-controlled RCTs of antipsychotic drugs, 
therefore, could be highly informative for the question of whether antipsychotics cause serious 
physical disorders through acutely-occurring side effects. We searched PubMed for meta-
analyses on this topic using the broad search string “((serious adverse event) OR SAE) AND 
(antipsychotic OR neuroleptic)” (last search 21.12.2018), but among 129 hits we found no such 
analysis. 
 
Added value of this study 
We included 597 studies and 108664 patients across indications and analyzed the occurrence 
of somatic SAEs with antipsychotics compared to placebo. With the outcome somatic SAEs, 
we focused on physical side effects. We found evidence that antipsychotics increase somatic 
SAEs even in relatively short-term trials ((88% ≤3 month). Elderly, and with weaker evidence 
children and adolescents, appeared to be at higher risk as compared to adults. 
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Implications of all available evidence 
Clinicians should be aware that antipsychotics are potentially toxic drugs and use them carefully 
– especially when treating patients that appear particularly vulnerable such as the elderly, and 
possibly children and adolescents.  
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Figure 1: Study selection 
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TABLES 
 
Table 1: Results of primary and secondary outcomes 
 Studies Total Drug Placebo Results 
Primary and 
secondary 
outcomes 
Studies 
with 
data (K) 
Studies 
with at 
least one 
event (k) 
Patients with at 
least one event 
(%) 
 
at minimum 
at maximum 
Patients in 
studies 
with data 
(N) 
Patients in 
studies 
with at 
least one 
event (n) 
Patients with at 
least one event 
(%) 
 
at minimum 
at maximum 
Patients in 
studies 
with data 
(N) 
Patients in 
studies 
with at 
least one 
event (n) 
Patients with at 
least one event 
(%) 
 
at minimum 
at maximum 
Patients in 
studies 
with data 
(N) 
Patients in 
studies 
with at 
least one 
event (n) 
OR (95% CI) 
Somatic SAE 314 196  1041 (1.54%) 1281 (1.89%) 67642 57850 
698 (1.63%) 
862 (2.02%) 42600 37073 
343 (1.37%) 
419 (1.67%) 25042 20777 
1.24 (1.08, 1.42) 
1.24 (1.10, 1.41) 
Psychiatric SAE 314 186 1884 (2.79%) 2082 (3.08%) 67598 56381 
1038 (2.43%) 
1161 (2.72%) 42606 36307 
846 (3.39%) 
921 (3.69%) 24992 20074 
0.64 (0.58, 0.71) 
0.67 (0.61, 0.73) 
Any SAE 368 276 4084 (4.55%) 89731 84999 2445 (4.3%) 56870 54343 1639 (4.99%) 32861 30656 0.83 (0.77, 0.89) 
 
The number of studies with data (K) includes studies where no event occurred. The proportion of patients with at least one event is with respect to the total number of patients 
with data on the outcome (N), i.e., including all studies with data (K). OR=odds ratio. 95% CI=95% confidence interval. 
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Table 2: Sensitivity analyses 
 Studies Total Drug Placebo Results 
Sensitivity 
analyses 
Studies 
with 
data on 
somatic 
SAEs 
(K) 
Studies 
with at 
least one 
somatic 
SAE (k) 
Patients with at 
least one 
somatic SAE 
(%) 
 
at minimum 
at maximum 
Patients in 
studies 
with data 
on somatic 
SAEs (N) 
Patients in 
studies 
with at 
least one 
somatic 
SAE (n) 
Patients with at 
least one 
somatic SAE 
(%) 
 
at minimum 
at maximum 
Patients in 
studies 
with data 
on somatic 
SAEs (N) 
Patients in 
studies 
with at 
least one 
somatic 
SAE (n) 
Patients with at 
least one 
somatic SAE 
(%) 
 
at minimum 
at maximum 
Patients in 
studies 
with data 
on somatic 
SAEs (N) 
Patients in 
studies 
with at 
least one 
somatic 
SAE (n) 
OR (95% CI) 
SAEs during 
randomised 
phase only (plus 
24h) 
162 59 362 (1.69%) 388 (1.81%) 21459 15265 
266 (2.0%) 
285 (2.1%) 13361 9956 
96 (1.2%) 
103 (1.3%) 8098 5309 
1.60 (1.25, 2.04) 
1.61 (1.27, 2.04)* 
Peto’s model 
314 196 1041 (1.54%) 1281 (1.89%) 67642 57850 
698 (1.63%) 
862 (2.02%) 42600 37073 
343 (1.37%) 
419 (1.67%) 25042 20777 
1.23 (1.08, 1.41) 
1.23 (1.09, 1.39)* 
Bayesian 
common-effects 
model 
1.23 (1.07, 1.40) 
1.23 (1.09, 1.40)† 
Bayesian 
random-effects 
model 
1.17 (1.00, 1.36) 
1.14 (0.96, 1.33)† 
Correlated beta-
binomial 
(Sarmanov) 
model 
1.23 (0.98; 1.55) 
1.25 (1.00; 1.58) 
Treatment-
related SAEs 
(SAR, judged by 
original 
investigators) ‡ 
183 37 89 (0.29%) 97 (0.32%) 30571 12354 
61 (0.32%) 
66 (0.34%) 19148 8368 
28 (0.25%) 
31 (0.27%) 11423 3986 
1.29 (0.82, 2.04) 
1.27 (0.82, 1.96)     
Double-blind 
studies only 306 194 
1037 (1.54%) 
1277 (1.9%) 67272 57783 
695 (1.64%) 
859 (2.03%) 42394 37038 
342 (1.37%) 
418 (1.68%) 24878 20745 
1.24 (1.08, 1.42) 
1.24 (1.09, 1.40) 
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Studies 
with 
data on 
somatic 
SAEs 
(K) 
Studies 
with at 
least one 
somatic 
SAE (k) 
Patients with at 
least one 
somatic SAE 
(Patients with at 
least one 
somatic SAE 
per 1000 
patient-years) 
 
at minimum 
at maximum 
Patient-
years in 
studies 
with data 
on somatic 
SAEs 
(number 
of 
patients) 
Patient-
years in 
studies 
with at 
least one 
somatic 
SAE 
(number 
of 
patients) 
Patients with at 
least one 
somatic SAE 
(Patients with at 
least one 
somatic SAE 
per 1000 
patient-years) 
 
at minimum 
at maximum 
Patient-
years in 
studies 
with data 
on somatic 
SAEs 
(number 
of 
patients) 
Patient-
years in 
studies 
with at 
least one 
somatic 
SAE 
(number 
of 
patients) 
Patients with at 
least one 
somatic SAE 
(Patients with at 
least one 
somatic SAE 
per 1000 
patient-years) 
 
at minimum 
at maximum 
Patient-
years in 
studies 
with data 
on somatic 
SAEs 
(number 
of 
patients) 
Patient-
years in 
studies 
with at 
least one 
somatic 
SAE 
(number 
of 
patients) 
IRR (95% CI) 
Incidence rates 
 150 57 
359 (187) 
385 (200) 
2645 
(21533) 
1921 
patient-
years 
(15032 
patients) 
264 (211) 
283 (227) 
1641 
patient-
years 
(13387 
patients) 
1248 
patient-
years 
(9843 
patients) 
95 (147) 
102 (152) 
1007 
patient-
years 
(8146 
patients) 
673 
patient-
years  
(5189 
patients) 
1.46 (1.08, 1.96) 
1.45 (1.09, 1.94) 
(random effects 
generalized linear 
model)* 
 
The number of studies with data (K) includes studies where no event occurred. The proportion of patients with at least one event is with respect to the total number of patients 
with data on the outcome (N), i.e., including all studies with data (K). OR=odds ratio. IRR=incidence rate ratio. 95% CI=95% confidence interval. 95% CrI=95% credible 
interval. 
*OR (95% CI).  
†OR (95% CrI). 
‡12 studies provided information about treatment-related somatic SAEs only. Thus, they are included in this sensitivity analysis but not in the primary analysis (appendix: 
characteristic of included studies).   
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Table 3: Subgroup analyses 
 Studies Total Drug Placebo Results 
Subgroup analyses 
Studies 
with data 
on 
somatic 
SAEs (K) 
Studies 
with at 
least one 
somatic 
SAE (k) 
Patients with 
at least one 
somatic SAE 
(%) 
 
at minimum 
at maximum 
Patients in 
studies with 
data on 
somatic 
SAEs (N) 
Patients in 
studies with 
at least one 
somatic 
SAE (n) 
Patients with 
at least one 
somatic SAE 
(%) 
 
at minimum 
at maximum 
Patients in 
studies with 
data on 
somatic 
SAEs (N) 
Patients in 
studies with 
at least one 
somatic 
SAE (n) 
Patients with 
at least one 
somatic SAE 
(%) 
 
at minimum 
at maximum 
Patients in 
studies with 
data on 
somatic 
SAEs (N) 
Patients in 
studies with 
at least one 
somatic 
SAE (n) 
OR (95% CI) 
Test for 
subgrou
p 
differen
ces 
 
STUDY 
DURATION              
1 < 6 days 12 6 10 (0.54%) 10 (0.54%) 1850 1400 
10 (0.75%) 
10 (0.75%) 1336 1073 
0 (0%) 
0 (0%) 514 327 not estimable 
p>0.99 
p>0.99 6 days – 13 weeks 264 160 
865 (1.5%) 
1066 (1.85%) 57635 48861 
588 (1.6%) 
728 (1.98%) 36813 31853 
277 (1.33%) 
338 (1.62%) 20822 17008 
1.22 (1.05. 1.42) 
1.23 (1.08. 1.41) 
> 13 weeks 38 30 166 (2.04%) 205 (2.51%) 8157 7589 
100 (2.25%) 
124 (2.79%) 4451 4147 
66 (1.78%) 
81 (2.19%) 3706 3442 
1.24 (0.90. 1.70) 
1.22 (0.91. 1.63) 
AGE GROUP*              
Children and 
adolescents 42 23 
53 (0.88%) 
58 (0.96%) 6047 4191 
36 (0.96%) 
40 (1.07%) 3731 2632 
17 (0.73%) 
18 (0.78%) 2316 1559 
1.49 (0.81. 2.75) 
1.54 (0.85. 2.77) 
p=0.05 
p=0.03 Adults 246 153 
612 (1.09%) 
810 (1.44%) 56301 48707 
394 (1.11%) 
528 (1.48%) 35585 31368 
218 (1.05%) 
282 (1.36%) 20716 17339 
1.09 (0.91. 1.29) 
1.10 (0.95. 1.28) 
Elderly 23 20 376 (7.25%) 413 (7.96%) 5189 4952 
268 (8.29%) 
294 (9.10%) 3232 3073 
108 (5.52%) 
119 (6.08%) 1957 1879 
1.56 (1.22. 1.98) 
1.58 (1.25. 1.99) 
COMBINATIONS 
OF DRUGS†              
Monotherapy 223 152 891 (1.63%) 1094 (2.00%) 54689 47693 
620 (1.75%) 
760 (2.15%) 35350 31426 
271 (1.4%) 
334 (1.37%) 19339 16267 
1.30 (1.12. 1.52) 
1.29 (1.12. 1.47) p=0.06 
p=0.10 
Any combination 78 38 122 (1.02%) 156 (1.31%) 11928 9390 
62 (0.92%) 
83 (1.24%) 6713 5270 
60 (1.15%) 
73 (1.4%) 5215 4120 
0.90 (0.62. 1.29) 
0.96 (0.69. 1.32) 
Add-on to 
antidepressants 34 14 
40 (0.66%) 
42 (0.69%) 6088 4299 
21 (0.58%) 
21 (0.58%) 3609 2547 
19 (0.77%) 
21 (0.85%) 2479 1752 
0.89 (0.47. 1.67) 
0.79 (0.43. 1.47) 
p=0.90 
p=0.97 
Add-on to 
antipsychotics 10 2 
2 (0.5%) 
2 (0.5%) 403 137 
1 (0.49%) 
1 (0.49%) 205 67 
1 (0.51%) 
1 (0.51%) 198 70 
1.05 (0.06. 17.23) 
1.05 (0.06. 17.23) 
Add-on to mood 
stabilizers 24 16 
53 (1.23%) 
78 (1.8%) 4323 4145 
24 (1.03%) 
39 (1.68%) 2321 2230 
29 (1.45%) 
39 (1.95%) 2002 1915 
0.74 (0.42. 1.29) 
0.86 (0.54. 1.36) 
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DIAGNOSTIC 
CATEGORY              
Acute agitation 1 0 0 (0%) 0 (0%) 120 0 
0 (0%) 
0 (0%) 60 0 
0 (0%) 
0 (0%) 60 0 not estimable 
p=0.43 
p=0.24 
ADHD or 
disruptive 
behaviour disorder 
6 3 14 (1.75%) 14 (1.75%) 800 495 
6 (1.51%) 
6 (1.51%) 398 250 
8 (1.99%) 
8 (1.99%) 402 245 
0.71 (0.24. 2.10) 
0.71 (0.24. 2.10) 
Anorexia nervosa 3 1 2 (2.53%) 2 (2.53%) 79 15 
2 (5.56%) 
2 (5.56%) 36 6 
0 (0%) 
0 (0%) 43 9 
10.56 (0.41. 268.69) 
10.56 (0.41. 268.69) 
Anxiety disorder 9 3 13 (0.69%) 13 (0.69%) 1874 889 
5 (0.53%) 
5 (0.53%) 948 445 
8 (0.86%) 
8 (0.86%) 926 444 
0.61 (0.19. 1.91) 
0.61 (0.19. 1.91) 
Autism or pervasive 
developmental 
disorder 
10 6 11 (1.11%) 11 (1.11%) 991 680 
7 (1.19%) 
7 (1.19%) 589 424 
4 (1.00%) 
4 (1.00%) 402 256 
1.25 (0.33. 4.65) 
1.25 (0.33. 4.65) 
Bipolar disorder 81 61 225 (1.11%) 304 (1.5%) 20214 18748 
145 (1.2%) 
196 (1.62%) 12089 11251 
80 (0.98%) 
108 (1.33%) 8125 7497 
1.29 (0.97. 1.71) 
1.31 (1.03. 1.68) 
Borderline 
personality disorder 4 2 
6 (0.67%) 
13 (1.44%) 900 765 
4 (0.74%) 
8 (1.48%) 539 453 
2 (0.55%) 
5 (1.39%) 361 312 
1.32 (0.23. 7.53) 
1.03 (0.33. 3.22) 
Chemotherapy-
induced nausea and 
vomiting 
1 0 0 (0%) 0 (0%) 44 0 
0 (0%) 
0 (0%) 22 0 
0 (0%) 
0 (0%) 22 0 not estimable 
Dementia 15 14 351 (8.69%) 382 (9.75%) 3916 3712 
253 (9.86%) 
273 (10.64%) 2566 2429 
98 (7.26%) 
109 (8.07%) 1350 1283 
1.59 (1.23. 2.04) 
1.56 (1.23. 1.99) 
Drug abuse 18 8 35 (2.55%) 36 (2.62%) 1375 880 
19 (2.64%) 
20 (2.78%) 719 437 
16 (2.44%) 
16 (2.44%) 656 443 
1.21 (0.61. 2.40) 
1.28 (0.65. 2.51) 
Dysthymia 1 0 0 (0%) 0 (0%) 39 0 
0 (0%) 
0 (0%) 20 0 
0 (0%) 
0 (0%) 19 0 not estimable 
Fibromyalgia 1 0 0 (0%) 0 (0%) 51 0 
0 (0%) 
0 (0%) 25 0 
0 (0%) 
0 (0%) 26 0 not estimable 
Gambling addiction 2 0 0 (0%) 0 (0%) 63 0 
0 (0%) 
0 (0%) 30 0 
0 (0%) 
0 (0%) 33 0 not estimable 
Healthy subjects 12 2 3 (0.81%) 3 (0.81%) 369 80 
2 (0.88%) 
2 (0.88%) 227 52 
1 (0.7%) 
1 (0.7%) 142 28 
1.08 (0.10. 11.84) 
1.08 (0.10. 11.84) 
Major depressive 
disorder 28 15 
40 (0.56%) 
42 (0.58%) 7184 5703 
24 (0.55%) 
24 (0.55%) 4356 3457 
16 (0.57%) 
18 (0.64%) 2828 2246 
1.05 (0.55. 2.00) 
0.92 (0.49. 1.73) 
Obsessive 
compulsive disorder 6 1 
4 (1.47%) 
4 (1.47%) 272 40 
1 (0.68%) 
1 (0.68%) 147 20 
3 (2.4%) 
3 (2.4%) 125 20 
0.30 (0.03. 3.15) 
0.30 (0.03. 3.15) 
Parkinson’s disease 3 3 12 (6.56%) 18 (9.84%) 183 183 
9 (8.65%) 
15 (14.42%) 104 104 
3 (3.8%) 
3 (3.8%) 79 79 
2.69 (0.69. 10.52) 
4.21 (1.15. 15.37) 
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Post-traumatic 
stress disorder 6 3 
19 (4.42%) 
19 (4.42%) 430 376 
10 (4.67%) 
10 (4.67%) 214 187 
9 (4.17%) 
9 (4.17%) 216 189 
1.13 (0.45. 2.83) 
1.13 (0.45. 2.83) 
Schizophrenia 100 73 303 (1.07%) 417 (1.48%) 28252 25149 
208 (1.08%) 
290 (1.51%) 19202 17469 
95 (1.05%) 
127 (1.40%) 9050 7681 
0.99 (0.77. 1.28) 
1.02 (0.82. 1.27) 
Stuttering 2 0 0 (0%) 0 (0%) 40 0 
0 (0%) 
0 (0%) 20 0 
0 (0%) 
0 (0%) 20 0 not estimable 
Tourette syndrome 5 1 3 (0.67%) 3 (0.67%) 446 135 
3 (1.04%) 
3 (1.04%) 289 90 
0 (0%) 
0 (0%) 157 45 
3.64 (0.18. 72.01) 
3.64 (0.18. 72.01) 
ANTIPSYCHOTIC 
SUBSTANCE‡              
Amisulpride 7 0 0 (0%) 0 (0%) 250 0 
0 (0%) 
0 (0%) 137 0 
0 (0%) 
0 (0%) 113 0 not estimable 
p=0.87 
p=0.93 
Aripiprazole 59 37 163 (1.37%) 189 (1.58%) 11926 10439 
101 (1.46%) 
115 (1.66%) 6925 6068 
62 (1.24%) 
74 (1.48%) 5001 4371 
1.35 (0.97. 1.86) 
1.28 (0.95. 1.73) 
Asenapine 16 13 44 (0.96%) 79 (1.72%) 4596 4027 
26 (0.92%) 
45 (1.59%) 2836 2451 
18 (1.02%) 
34 (1.93%) 1760 1576 
0.92 (0.50. 1.58) 
0.93 (0.60. 1.46) 
Brexpiprazole 9 6 21 (0.59%) 21 (0.59%) 3534 2827 
16 (0.67%) 
16 (0.67%) 2375 1863 
5 (0.43%) 
5 (0.43%) 1159 964 
1.75 (0.63. 4.84) 
1.75 (0.63. 4.84) 
Cariprazine 4 2 8 (0.41%) 8 (0.41%) 1971 822 
5 (0.39%) 
5 (0.39%) 1273 554 
3 (0.43%) 
3 (0.43%) 698 268 
0.89 (0.21. 3.70) 
0.89 (0.21. 3.70) 
Chlorpromazine 1 1 1 (0.94%) 1 (0.94%) 106 106 
1 (1.89%) 
1 (1.89%) 53 53 
0 (0%) 
0 (0%) 53 53 not estimable 
Haloperidol 17 15 90 (2.79%) 105 (3.26%) 3225 3071 
52 (3.14%) 
64 (3.86%) 1658 1584 
38 (2.43%) 
41 (2.62%) 1567 1487 
1.39 (0.89. 2.15) 
1.61 (1.07. 2.43) 
Iloperidone 5 4 19 (0.96%) 43 (2.17%) 1984 1964 
12 (0.87%) 
30 (2.18%) 1379 1369 
7 (1.16%) 
13 (2.15%) 605 595 
0.74 (0.29. 1.90) 
0.99 (0.51. 1.93) 
Lurasidone 14 12 37 (0.84%) 45 (1.02%) 4423 4065 
21 (0.75%) 
28 (0.99%) 2818 2610 
16 (1%) 
17 (1.06%) 1605 1455 
0.81 (0.41. 1.59) 
1.00 (0.54. 1.87) 
Olanzapine 68 40 248 (2.07%) 310 (2.58%) 12004 9999 
178 (2.5%) 
215 (3.03%) 7106 6101 
70 (1.43%) 
95 (1.94%) 4898 3898 
1.46 (1.09. 1.96) 
1.35 (1.04. 1.74) 
Paliperidone 27 21 97 (1.28%) 130 (1.71%) 7590 7122 
64 (1.32%) 
89 (1.83%) 4864 4592 
33 (1.21%) 
41 (1.5%) 2726 2530 
1.09 (0.71. 1.68) 
1.23 (0.84. 1.80) 
Quetiapine 53 27 106 (1.23%) 109 (1.27%) 8597 6189 
59 (1.21%) 
60 (1.23%) 4886 3651 
47 (1.27%) 
49 (1.32%) 3711 2538 
1.02 (0.68. 1.53) 
1.00 (0.67. 1.49) 
Risperidone 55 38 245 (2.88%) 288 (3.38%) 8513 7280 
145 (3.17%) 
170 (3.71%) 4581 3971 
100 (2.54%) 
118 (3%) 3932 3309 
1.32 (1.02. 1.73) 
1.33 (1.04. 1.70) 
Ziprasidone 18 10 25 (0.95%) 32 (1.21%) 2645 2431 
14 (0.94%) 
20 (1.35%) 1484 1380 
11 (0.95%) 
12 (1.03%) 1161 1051 
0.96 (0.41. 2.24) 
1.22 (0.57. 2.64) 
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Zotepine 3 2 5 (1.6%) 5 (1.6%) 312 227 
3 (1.94%) 
3 (1.94%) 155 116 
2 (1.27%) 
2 (1.27%) 157 111 
1.43 (0.24. 8.54) 
1.43 0.24. 8.54) 
FGA/SGA¶              
FGA 18 16 91 (2.73%) 106 (3.18%) 3331 3177 
53 (3.1%) 
65 (3.8%) 1711 1637 
38 (2.37%) 
41 (2.53%) 1620 1540 
1.42 (0.91; 2.19) 
1.64 (1.09; 2.47) p=0.55 
p=0.19 
SGA 313 194 988 (1.5%) 1216 (1.85%) 65896 55725 
645 (1.58%) 
797 (1.95%) 40872 35090 
343 (1.37%) 
419 (1.67%) 25024 20635 
1.23 (1.07; 1.41) 
1.23 (1.08; 1.39) 
SPONSORSHIP §              
Sponsored by 
pharmaceutical 
company 
263 174 895 (1.52%) 1105 /1.87%) 59066 50694 
574 (1.6%) 
709 (1.97%) 35984 31159 
321 (1.39%) 
396 (1.72%) 23082 19535 
1.24 (1.08; 1.44) 
1.24 (1.09; 1.41] p=0.73 
p=0.81 Independent from 
pharmaceutical 
company 
41 18 
46 (1.2%) 
49 (1.28%) 
 
3819 2247 26 (1.28%) 28 (1.37%) 2039 1224 
20 (1.12%) 
21 (1.18%) 1780 1023 
1.12 (0.61; 2.03) 
1.15 (0.64; 2.07) 
 
The number of studies with data (K) includes studies where no event occurred. The proportion of patients with at least one event is with respect to the total number of patients 
with data on the outcome (N), i.e., including all studies with data (K). OR=odds ratio. 95% CI=95% confidence interval. 
* 3 studies (all without events) included patients of different age groups (N=105). 
† In an additional 13 studies (6 with events) with 1025 patients (767 patients in studies with events) with 28-31 events, antipsychotics were combined with illegal drugs. These 
studies were not included in this analysis. 
‡ No data on somatic SAEs was found for the antipsychotics clozapine and sertindole. Two studies allowed several second-generation antipsychotic drugs (79 patients on drug, 
70 patients on placebo). Chlorpromazine and haloperidol are included because these first generation antipsychotics were used as additional active comparators in placebo-
controlled studies of second-generation antipsychotics. Of note, this subgroup-analysis did not account for multiple uses of placebo-groups in multi-arm studies. 
§ For 10 studies sponsorship was unclear. 18 drug arms used as active comparators in industry-sponsored trials were excluded. 
¶ One study (Borlido 2016) was not included, because both, SGAs and FGAs, were used in the drug arm. We additionally meta-analysed head to head comparisons of FGAs and 
SGAs based on studies using FGAs as active comparators (appendix: additional analyses; minimum estimate OR 1.15 (95%CI 0.77. 1.70); maximum estimate OR 1.33 (95%CI 
0.92, 1.90).  
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Table 4: Meta-regression analyses 
 
 Studies Total Drug Placebo Results 
Meta-regression 
Studies 
with data 
on 
somatic 
SAEs (K) 
Studies 
with at 
least one 
somatic 
SAE (k) 
Patients with at 
least one somatic 
SAE (%) 
 
at minimum 
at maximum 
Patients in 
studies with 
data on 
somatic 
SAEs (N) 
Patients in 
studies with 
at least one 
somatic 
SAE (n) 
Patients with at 
least one somatic 
SAE (%) 
 
at minimum 
at maximum 
Patients in 
studies with 
data on 
somatic 
SAEs (N) 
Patients in 
studies with 
at least one 
somatic 
SAE (n) 
Patients with at 
least one somatic 
SAE (%) 
 
at minimum 
at maximum 
Patients in 
studies with 
data on 
somatic 
SAEs (N) 
Patients in 
studies with 
at least one 
somatic 
SAE (n) 
Regression 
coefficient  
(95% CrI) 
ANTIPSYCHOTIC 
DOSE 186 118 
450 (1.02%) 
583 (1.33%) 43947 37194 
289 (1.06%) 
375 (1.38%) 27262 23489 
161 (0.97%) 
208 (1.25%) 16680 13705 
0.017 
(-0.003, 0.037) 
0.023 
(0.004, 0.043)* 
PROPORTION OF 
WOMEN IN 
STUDY 
292 188 972 1208 66445 57043 
655 
816 41935 20436 
317 
392 24510 36607 
0.30 
(-0.40, 0.99) 
0.12 
(-0.63, 0.84)† 
 
The number of studies with data (K) includes studies where no event occurred. The proportion of patients with at least one event is with respect to the total number of patients 
with data on the outcome (N), i.e., including all studies with data (K). OR=odds ratio. 95% CI=95% confidence interval. 
*Regression coefficient for increase in logOR (logarithmic OR) per mg olanzapine equivalent, corresponding to an OR (minimum/maximum estimate) of 0.96/0.90 for studies 
with a mean dose of 5 mg olanzapine equivalents, 1.05/1.01 for a mean dose of 10 mg, 1.14/1.13 for a mean dose of 15 mg, 1.25/1.27 for a mean dose of 20 mg and 1.36/1.43 for 
a mean dose of 25 mg. 
†Regression coefficient for increase in logOR (logarithmic OR)  per 1% increase in women, corresponding to an OR (minimum/maximum estimate) of  1.13/1.13 for study 
populations with 25% female patients, 1.22/1.16 for those with 50% female patients and 1.31/1.20 for those with 75% female patients. 
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Table 5: Somatic SAEs grouped by MedDRA System-Organ-Class 
 Studies Total Drug Placebo Results 
System-Organ-
Class (SOC) 
Studies 
with 
data (K) 
Studies 
with at 
least one 
event (k) 
Patients with at 
least one event 
(%) 
 
at minimum* 
at maximum 
Patients in 
studies 
with data 
(N) 
Patients in 
studies 
with at 
least one 
event (n) 
Patients with at 
least one event 
(%) 
 
at minimum 
at maximum 
Patients in 
studies 
with data 
(N) 
Patients in 
studies 
with at 
least one 
event (n) 
Patients with at 
least one event 
(%) 
 
at minimum 
at maximum 
Patients in 
studies 
with data 
(N) 
Patients in 
studies 
with at 
least one 
event (n) 
OR (95% CI) 
Blood and 
lymphatic 
system disorders 
314 12 16 (0.02%) 
21 (0.03%) 
67642 4219 11 (0.03%) 13 (0.03%) 
42600 2839 
5 (0.02%) 
8 (0.03%) 25042 1380 
1.17 (0.37; 3.75) 
0.95 (0.36; 2.52) 
Cardiac 
disorders 314 54 
92 (0.14%) 
144 (0.21%) 
67642 19642 60 (0.14%) 98 (0.23%) 
42600 13030 
32 (0.13%) 
46 (0.18%) 
25042 6612 
1.03 (0.66; 1.61) 
1.22 (0.85; 1.75) 
Congenital, 
familial and 
genetic 
disorders 
314 1 1 (0%) 1 (0%) 67642 182 
1 (0%) 
1 (0%) 42600 120 
0 (0%) 
0 (0%) 25042 62 not estimable 
Ear and 
labyrinth 
disorders 
314 7 7 (0.01%) 7 (0.01%) 67642 2910 
3 (0.01%) 
3 (0.01%) 42600 2017 
4 (0.02%) 
4 (0.02%) 25042 893 
0.28 (0.05; 1.46) 
0.28 (0.05; 1.46) 
Eye disorders 314 5 7 (0.01%) 7 (0.01%) 67642 1548 
4 (0.01%) 
4 (0.01%) 42600 842 
3 (0.01%) 
3 (0.01%) 25042 706 
1.19 (0.26; 5.48) 
1.19 (0.26; 5.48) 
Gastrointestinal 
disorders 314 64 
79 (0.12%) 
108 (0.16%) 67642 23151 
51 (0.12%) 
69 (0.16%) 42600 15078 
28 (0.11%) 
39 (0.16%) 25042 8073 
1.08 (0.67; 1.74) 
1.10 (0.73; 1.66) 
General 
disorders and 
administration 
site conditions 
314 63 85 (0.13%) 109 (0.16%) 67642 21860 
54 (0.13%) 
68 (0.16%) 42600 13953 
31 (0.12%) 
41 (0.16%) 25042 7907 
1.11 (0.70; 1.76) 
1.05 (0.70; 1.57) 
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Hepatobiliary 
disorders 314 21 
22 (0.03%) 
23 (0.03%) 67642 8850 
15 (0.04%) 
16 (0.04%) 42600 6089 
7 (0.03%) 
7 (0.03%) 25042 2761 
1.07 (0.44; 2.61) 
1.11 (0.46; 2.70) 
Immune system 
disorders 314 4 
4 (0.01%) 
4 (0.01%) 67642 1121 
4 (0.01%) 
4 (0.01%) 42600 727 
0 (0%) 
0 (0%) 25042 394 not estimable 
Infections and 
infestations 314 88 
150 (0.22%) 
225 (0.33%) 67642 28479 
103 (0.24%) 
152 (0.36%) 42600 17966 
47 (0.19%) 
73 (0.29%) 25042 10513 
1.47 (1.02; 2.12) 
1.43 (1.06; 1.92) 
Injury, 
poisoning and 
procedural 
complications 
314 105 195 (0.29%) 258 (0.38%) 67642 35300 
128 (0.3%) 
168 (0.39%) 42600 22843 
67 (0.27%) 
90 (0.36%) 25042 12457 
1.15 (0.85; 1.56) 
1.13 (0.87; 1.48) 
Investigations 314 34 40 (0.06%) 51 (0.08%) 67642 9817 
28 (0.07%) 
36 (0.08%) 42600 6736 
12 (0.05%) 
15 (0.06%) 25042 3081 
1.23 (0.61; 2.45) 
1.25 (0.67; 2.35) 
Metabolism and 
nutrition 
disorders 
314 39 62 (0.09%) 83 (0.12%) 67642 14515 
43 (0.1%) 
56 (0.13%) 42600 9518 
19 (0.08%) 
27 (0.11%) 25042 4997 
1.25 (0.70; 2.21) 
1.12 (0.69; 1.85) 
Musculoskeletal 
and connective 
tissue disorders 
314 29 34 (0.05%) 37 (0.05%) 67642 10854 
27 (0.06%) 
29 (0.07%) 42600 6931 
7 (0.03%) 
8 (0.03%) 25042 3923 
2.51 (1.05; 6.01) 
2.46 (1.08; 5.58) 
Neoplasms 
benign, 
malignant and 
unspecified (incl 
cysts and 
polyps) 
314 25 27 (0.04%) 34 (0.05%) 67642 9055 
15 (0.04%) 
21 (0.05%) 42600 6123 
12 (0.05%) 
13 (0.05%) 25042 2932 
0.66 (0.30; 1.46) 
0.81 (0.39; 1.66) 
Nervous system 
disorders 314 114 
175 (0.26%) 
271 (0.4%) 67642 38436 
121 (0.28%) 
197 (0.46%) 42600 25362 
54 (0.22%) 
74 (0.3%) 25042 13074 
1.27 (0.92; 1.76) 
1.49 (1.13; 1.96) 
Pregnancy, 
puerperium and 
perinatal 
conditions 
314 5 5 (0.01%) 5 (0.01%) 67642 2189 
2 (0%) 
2 (0%) 42600 1476 
3 (0.01%) 
3 (0.01%) 25042 713 
0.33 (0.05; 2.28) 
0.33 (0.05; 2.28) 
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Product issues 314 1 1 (0%) 1 (0%) 67642 652 
1 (0%) 
1 (0%) 42600 523 
0 (0%) 
0 (0%) 25042 129 not estimable 
Renal and 
urinary 
disorders 
314 22 23 (0.03%) 30 (0.04%) 67642 8709 
16 (0.04%) 
20 (0.05%) 42600 5675 
7 (0.03%) 
10 (0.04%) 25042 3034 
1.39 (0.55; 3.51) 
1.24 (0.55; 2.76) 
Reproductive 
system and 
breast disorders 
314 9 9 (0.01%) 9 (0.01%) 67642 3972 
5 (0.01%) 
5 (0.01%) 42600 2467 
4 (0.02%) 
4 (0.02%) 25042 1505 
0.81 (0.20; 3.27) 
0.81 (0.20; 3.27) 
Respiratory, 
thoracic and 
mediastinal 
disorders 
314 38 55 (0.08%) 76 (0.11%) 67642 13007 
38 (0.09%) 
56 (0.13%) 42600 8590 
17 (0.07%) 
20 (0.08%) 25042 4417 
1.32 (0.74; 2.36) 
1.72 (1.02; 2.89) 
Skin and 
subcutaneous 
tissue disorders 
314 16 16 (0.02%) 20 (0.03%) 67642 6770 
12 (0.03%) 
15 (0.04%) 42600 4422 
4 (0.02%) 
5 (0.02%) 25042 2348 
1.76 (0.55; 5.57) 
1.67 (0.60; 4.62) 
Social 
circumstances 314 11 
11 (0.02%) 
12 (0.02%) 67642 4267 
6 (0.01%) 
7 (0.02%) 42600 2616 
5 (0.02%) 
5 (0.02%) 25042 1651 
0.80 (0.24; 2.68) 
0.91 (0.28; 2.93) 
Surgical and 
medical 
procedures 
314 8 21 (0.03%) 23 (0.03%) 67642 2430 
16 (0.04%) 
18 (0.04%) 42600 1390 
5 (0.02%) 
5 (0.02%) 25042 1040 
2.86 (0.99; 8.23) 
3.28 (1.16; 9.28) 
Vascular 
disorders 314 33 
43 (0.06%) 
56 (0.08%) 67642 12842 
30 (0.07%) 
41 (0.1%) 42600 8340 
13 (0.05%) 
15 (0.06%) 25042 4502 
1.40 (0.69; 2.82) 
1.82 (0.97; 3.41) 
 
The number of studies with data (K) includes studies where no event occurred. The proportion of patients with at least one event is with respect to the total number of patients 
with data on the outcome (N), i.e., including all studies with data (K). OR=odds ratio. 95% CI=95% confidence interval. 
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